Frontiers in Pharmacology · Nov 16, 2026

Weight Change and Cardiovascular Outcomes With GLP-1-Based Therapies A Systematic Review

By Riyaz Ahamed Shaik, Mohammad Shakil Ahmad, MOHAMMED ALJULIFI et al.

Introduction: GLP-1-based therapies affect body weight and cardiovascular outcomes, but the relationship between these effects remains uncertain. This systematic review described paired anthropometric and cardiovascular findings and assessed what the available evidence could establish about weight loss as a potential mediator. Methods: Five electronic sources were searched, and 22 human studies were included in a qualitative synthesis. Randomized studies reporting both weight change and clinical cardiovascular outcomes informed the main comparison; studies reporting only one outcome provided context. Randomized and observational evidence, placebo and active comparisons, and distinct endpoint definitions were considered separately. RoB 2, ROBINS-I, and GRADE were used. No individual participant data analysis or quantitative meta-analysis was performed. Results: The review included 19 randomized trials with 112,660 randomized participants and three observational studies with 568,760 reported participant entries; a unique combined population could not be established. In placebo-controlled trials in type 2 diabetes, three-point MACE HRs ranged from 0.73 to 0.91, with several trials showing reductions; ELIXA assessed four-point MACE and was neutral (HR 1.02; 95% CI 0.89–1.17). SELECT demonstrated lower three-point MACE in overweight or obesity without diabetes (HR 0.80; 95% CI 0.72–0.90). In SURPASS-CVOT, tirzepatide achieved greater weight loss and met noninferiority to dulaglutide, but superiority for MACE was not established (HR 0.92; 95.3% CI 0.83–1.01). Weight differences were reported separately in kilograms and percentage points; adolescent BMI change was a distinct outcome. Several randomized treatment effects had high-certainty evidence, but cross-trial comparisons did not identify a causal mediation effect of weight loss. Conclusion: GLP-1-based therapies reduced weight and improved selected cardiovascular and kidney outcomes in the populations studied. Cardiovascular effects were not clearly proportional to weight loss across heterogeneous trials, but this qualitative synthesis could not establish independence from weight loss or quantify mediation. Individual-level longitudinal mediation analyses were needed.

The paperJournal siteInterventions

AgingResearch.News